Manorama Industries Q1 FY27: Strong start, bigger capex cycle ahead

Manorama Industries began FY27 with a sharp jump in scale. In Q1 FY27, consolidated revenue reached INR 404.0 crores, up 39.5% year on year. EBITDA rose to INR 106.2 crores and PAT climbed to INR 78.7 crores, translating into a PAT margin of 19.5% versus 16.2% a year ago.

The quarter also crossed a milestone that management itself called out on the earnings call: the company exceeded INR 4,000 million in quarterly revenue for the first time. The management attributed the performance to sustained demand across key end-user industries, deeper customer engagement, and a higher contribution from value-added specialty fats and butters.

A notable element in the mix is geography. The company reported an export to domestic mix of 60:40 in Q1 FY27, highlighting how Manorama’s growth is tied to global confectionery, chocolate, and personal care demand, not only domestic consumption.

What powered the quarter

Manorama positions itself as a niche specialty fats platform built around exotic tree-borne oilseeds. The company’s product set includes stearin and olein fractions, cocoa butter equivalents under the MILCOA brand, and other specialty fats and butters used in chocolate, confectionery and personal care.

Operationally, management pointed to improved utilization of expanded fractionation capacity. The presentation states FY26 fractionation capacity at 47,500 TPA, including 25,000 MTPA commercialized in July 2025 and a 7,500 MTPA increase via debottlenecking in March 2026. In the concall, management said utilization for the quarter was around 80%.

However, the results table also shows a shift in gross profit profile. Q1 FY27 gross margin was 43.6% compared with 47.4% in Q1 FY26. The company still expanded EBITDA margin slightly to 26.3%, suggesting cost control and operating leverage partly offset the gross margin compression.

Financial snapshot

On the call, management also clarified that other income was unusually high in Q1 FY27. Other income was INR 16.18 crores, of which INR 13 crores was forex gains and the rest was largely FDR income. Management said this should normalize, which is an important point when looking at earnings quality.

Expansion agenda: from 47,500 TPA to the next platform

The company is now preparing for a larger investment cycle. The investor presentation outlines a proposed capex of INR 460 crores over the next 2 to 3 years, with major projects targeted for commissioning by FY28.

The expansion priorities described in the presentation include increasing fractionation capacity to 52,000 TPA through debottlenecking, adding a new 75,000 TPA fractionation Plant-3, and creating new CBA and ESOS capability. The company also plans to scale refining, including an addition of 300 TPD refining capability, with a planned 90,000 TPA refinery as part of the forward-integration program.

The concall added near-term numbers to the plan. Management guided FY27 capex spending at roughly INR 225 to 250 crores. They also said debottlenecking itself is a relatively small spend, about INR 5 to 6 crores, while most of the capital will go into the broader capacity build-out.

The timing is also clearer from the call. Management said solvent fractionation Plant-3 and refinery projects are targeted for commissioning around Q3 FY28. Even then, they cautioned that utilization ramp-up will be gradual, with fuller impact more visible in FY29.

Backward integration in Africa and the Burkina Faso bet

A major theme in both the presentation and the concall is control over raw material sourcing. Manorama sources sal, mango and other seeds across India, and shea nuts and shea butters from West African origins. The presentation lists multiple wholly owned subsidiaries across African sourcing locations and also lists market access subsidiaries in UAE and Brazil.

In Q1 FY27, the company made two Africa-related moves. It incorporated a wholly owned subsidiary in the Republic of Chad and acquired about 10 hectares of land in Burkina Faso for a shea processing facility, with regulatory approvals pending.

The Burkina Faso project is positioned as more than a procurement outpost. Management said it will deepen backward integration, improve supply security and traceability, and reduce freight of seeds into India. They also quantified the economics: the Burkina Faso capex is expected to be around INR 120 to 130 crores, with a payback period of around 3 years once operational.

This quantified payback is one of the few explicit return-linked statements in the materials, and it helps investors evaluate whether integration is being pursued with discipline rather than only as a narrative.

Latin America: early signs through Brazil partnership

Manorama has also started building a manufacturing and market access route in Latin America. Through its subsidiary, Manorama Latin America LTDA, the company partnered with DEKEL Agroindustria in Brazil to produce cocoa butter equivalents and specialty fats.

The presentation states the first commercial production batch at DEKEL was accomplished in Q3 FY26, and trial samples were delivered to customers. In Q1 FY27 discussions, management described the Brazil unit as still in a trial and build-out phase, and said ramp-up will likely be gradual over the next 2 to 4 quarters. Management did not quantify potential revenue contribution from Brazil at this stage.

Takeaways for investors

Manorama’s Q1 FY27 performance reinforces the scaling capability of its specialty fats model. Revenue grew 39.5% YoY and profitability outpaced revenue growth, with PAT up 67.6% YoY. At the same time, the quarter carried a higher other income contribution driven by forex gains, which management said should normalize.

The strategic picture is now dominated by the next capex cycle. A proposed INR 460 crore expansion program, supported by the INR 500 crore QIP completed in July 2026, is aimed at expanding fractionation and refining, premiumising the product mix, and deepening supply chain integration.

Execution and timing will matter. Regulatory approvals for Burkina Faso remain pending, and management itself highlighted that utilization ramp-up for new plants is gradual. Freight and geopolitical volatility also remain a cost risk, and the quarter’s gross margin decline shows that mix and input costs can still swing.

Still, the company enters FY27 with a strong base run rate, a clearer capex roadmap, and an expanding global footprint across sourcing and customers. The next few quarters will be watched for capacity debottlenecking progress, Brazil ramp-up, and how efficiently the company converts the enlarged platform into sustained returns.